scholarly journals Coronavirus Endoribonuclease Ensures Efficient Viral Replication and Prevents Protein Kinase R Activation

2020 ◽  
Author(s):  
Jing Zhao ◽  
Lu Sun ◽  
Ye Zhao ◽  
Delan Feng ◽  
Jinlong Cheng ◽  
...  

Coronavirus (CoV) nsp15 is an endoribonuclease conserved throughout the CoV family. The enzymatic activity and crystal structure of infectious bronchitis virus (IBV) nsp15 are undefined, and the protein’s role in replication remains unclear. We verified the uridylate-specific endoribonuclease (EndoU) activity of IBV and found that the EndoU active sites were located in the C-terminus of nsp15 and included His223, His238, Lys278 and Tyr334. We further constructed an infectious clone of the IBV-rSD strain (rSD-wild-type [WT]) and EndoU-deficient IBVs by changing the codon for the EndoU catalytic residues to alanine. Both the rSD-WT and EndoU-deficient viruses propagated efficiently in embryonated chicken eggs. Conversely, EndoU-deficient viral propagation was severely impaired in chicken embryonic kidney cells, which was reflected in the lower viral mRNA accumulation and protein synthesis. After infecting chickens with the parental rSD-WT strain and EndoU-deficient viruses, the EndoU-deficient-virus-infected chickens presented reduced mortality, tissue injury and viral shedding. IMPORTANCE Coronaviruses can emerge from animal reservoirs into naive host species to cause pandemic respiratory and gastrointestinal diseases with significant mortality in humans and domestic animals. Infectious bronchitis virus (IBV), a γ-coronavirus, infects respiratory, renal and reproductive systems, causing millions of dollars in lost revenue worldwide annually. Mutating the viral endoribonuclease resulted in an attenuated virus and prevented protein kinase R activation. Therefore, EndoU activity is a virulence factor in IBV infections, thus providing an approach for generating live-attenuated vaccine candidates for emerging coronaviruses.

Viruses ◽  
2018 ◽  
Vol 10 (11) ◽  
pp. 652
Author(s):  
Seung-Min Hong ◽  
Se-Hee An ◽  
Chung-Young Lee ◽  
Chang-Seon Song ◽  
Kang-Seuk Choi ◽  
...  

We established a cold-adapted infectious bronchitis virus (BP-caKII) by passaging a field virus through specific pathogen-free embryonated eggs 20 times at 32 °C. We characterized its growth kinetics and pathogenicity in embryonated eggs, and its tropism and persistence in different tissues from chickens; then, we evaluated pathogenicity by using a new premature reproductive tract pathogenicity model. Furthermore, we determined the complete genomic sequence of BP-caKII to understand the genetic changes related to cold adaptation. According to our results, BP-caKII clustered with the KII genotype viruses K2 and KM91, and showed less pathogenicity than K2, a live attenuated vaccine strain. BP-caKII showed delayed viremia, resulting in its delayed dissemination to the kidneys and cecal tonsils compared to K2 and KM91, the latter of which is a pathogenic field strain. A comparative genomics study revealed similar nucleotide sequences between BP-caKII, K2 and KM91 but clearly showed different mutations among them. BP-caKII shared several mutations with K2 (nsp13, 14, 15 and 16) following embryo adaptation but acquired multiple additional mutations in nonstructural proteins (nsp3, 4 and 12), spike proteins and nucleocapsid proteins following cold adaptation. Thus, the establishment of BP-caKII and the identified mutations in this study may provide insight into the genetic background of embryo and cold adaptations, and the attenuation of coronaviruses.


2020 ◽  
Vol 51 (6) ◽  
pp. 621-626
Author(s):  
Lana Ljuma Skupnjak ◽  
Anto Vrdoljak ◽  
Nikol Očuršćak

The most effective means of controlling infectious bronchitis in poultry is by vaccination. Live attenuated vaccines based on the H120 strain (Mass serotype) are the most commonly used vaccines. Since vaccination is often performed in the hatchery, long duration of immunity is preferred. Avishield IB H120, a live attenuated vaccine based on the strain H120 is registered across the European Union and other countries, and has a declared immunity period of up to 5 weeks after vaccination. This study presents the results of an additional survey demonstrating protection against challenge with the IBV strain M41 up to 8 weeks after a single vaccination with Avishield IB H120. Seven weeks after vaccination, 94% of chickens vaccinated by spray were protected against the challenge. Eight weeks after vaccination, 80% of spray vaccinated chickens and 75% of orally vaccinated chickens were still protected against the challenge with virulent IBV.


Sign in / Sign up

Export Citation Format

Share Document